Alpha Tau Medical (NASDAQ:DRTS) presented early clinical results from the first three patients treated in its REGAIN study of ...

The third patient showed stable disease with a 30% reduction in tumor size. ・Alpha Tau reported no unexpected serious adverse events through May 3, 2026. ・As of the cutoff date, none of the patients ...

Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the innovative alpha-radiation ...

First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the path towards potential FDA ...

Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®, today announced that an abstract entitled “Combined Safety and ...

JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has ...

Radiation is energy that moves from one place to another in a form that can be described as waves or particles. We are exposed to radiation in our everyday life. Some of the most familiar sources of ...

Abstract from trial evaluating Alpha DaRT® in combination with pembrolizumab in elderly patients with locally advanced and ...

In the middle of the 20th century, the atom was all the rage. Radiation was the shiny new solution to everything while being similarly poorly understood by the general public and a great deal of those ...